1. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020.;Oliver;MMWR Morb Mortal Wkly Rep,2020
2. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020.;Dooling;MMWR Morb Mortal Wkly Rep,2020
3. Vaccine-associated hypersensitivity.;McNeil;J Allergy Clin Immunol,2018
4. CDC. COVID-19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
5. CDC. COVID-19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html